Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY -6.00%67 3-Year EBITDA Growth Rate is 17.50% as of Jun. 2026, which is at its 10-year median of 17.50. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.40 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 813 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 64.58% on this metric.
During the past 12 months, Swedish Orphan Biovitrum AB's average EBITDA Per Share Growth Rate was 28.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 25.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Swedish Orphan Biovitrum AB was 97.90% per year. The lowest was -42.70% per year. And the median was 17.50% per year.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Swedish Orphan Biovitrum AB 3-Year EBITDA Growth Rate Related Terms
SWOBY vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's 3-Year EBITDA Growth Rate falls into.
Swedish Orphan Biovitrum AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.50% mean?
Swedish Orphan Biovitrum AB (SWOBY) has a 3-Year EBITDA Growth Rate of 17.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Swedish Orphan Biovitrum AB and its competitors. This is near median its historical median of 17.50. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #288 out of 813 companies in the Drug Manufacturers industry, placing it in the top 35.4%.
Is Swedish Orphan Biovitrum AB's 3-Year EBITDA Growth Rate too high?
Swedish Orphan Biovitrum AB's current 3-Year EBITDA Growth Rate of 17.50% is near median its 10-year median of 17.50. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Swedish Orphan Biovitrum AB's value of 17.50% is 98.9% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #288 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #288 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Swedish Orphan Biovitrum AB's value of 17.50% is 98.9% above this benchmark. While the company's 10-year median is 17.50 vs. the industry median of 8.80, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current 3-Year EBITDA Growth Rate of 17.50% is 98.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current 3-Year EBITDA Growth Rate is 17.50%, which is near median its own 10-year median of 17.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.40, compared to a current price of $23.50 — trading 27.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.50%, which is near median its 10-year median of 17.50 and 98.9% above the Drug Manufacturers industry median of 8.80. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current 3-Year EBITDA Growth Rate is 17.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.50 is trading 27.7% above its estimated GF Value™ of $18.40.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for SWOBY:
3-Year EBITDA Growth Rate: 17.50% (near median its 10-year median of 17.50)
GF Value™: $18.40 vs. price of $23.50 (27.7% above fair value)
Industry Position: 98.9% above the Drug Manufacturers median (#288 of 813)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
